Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

This is a multi-center, open-label, Phase Ⅰ/Ⅱ clinical study of ZG006 for the treatment of participants with small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment.

Trial Details

NCT ID
NCT05978284
Phase
PHASE1 / PHASE2
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • ZG006
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Fully understand the study and voluntarily sign the informed consent form;
  • Male or female 18\~75 years of age;
  • Histologically or cytologically confirmed diagnosis of small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), who had no standard treatment…
  • Archival tissue sample or fresh biopsy tissue sample must be available for DLL3 detection;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →